Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access
Source: SeekingAlpha
2026-05-07 00:22:01 ET
More on Zevra Therapeutics, Inc.
- Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
- Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
- Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
- Zevra Therapeutics, Inc. GAAP EPS of $0.60 beats by $0.52, revenue of $36.2M beats by $4.24M
- Zevra Therapeutics, Inc. Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access
Zevra Therapeutics Inc.
NASDAQ: ZVRA
ZVRA Trading
-5.92% G/L:
$12.16 Last:
792,223 Volume:
$12.80 Open:
ZVRA Latest News
$484,721,776
54,946,394
0.39%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Celebration
